Drug Trial Radar · NCT00467259
Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women
Last checked: Nov 19, 2026Latest source record: Dec 15, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,271
Actual
Start
Apr 2007
Primary completion
Jan 2009
Study completion Jan 2009
Sponsor
- Lead sponsor
- Warner ChilcottIndustry
- Sponsor type
- Industry
- First posted
- Apr 30, 2007
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- Female only, from 45 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is designed to evaluate the endometrial safety of a testosterone patch as treatment for low libido in naturally postmenopausal women.
Conditions
- Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal SystemDrug
Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
Placebo patchDrug
placebo patch, changed twice a week for 52 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Endometrial Hyperplasia in Naturally Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Not Using Concomitant Estrogen and Progestin, Year 1Time frame: 52 weeks
Locations
115 sites in 1 country. Site status is shown where the registry gives one.
Study Facility
Birmingham, Alabama
Research Facility
Birmingham, Alabama
Research Facility
Mobile, Alabama
Research Facility
Montgomery, Alabama
Test Facility
Chandler, Arizona
Study Facility
Peoria, Arizona
Research Facility
Phoenix, Arizona
Research Facility
Phoenix, Arizona
Research Facility
Scottsdale, Arizona
Research Site
Tucson, Arizona
Research Facility
Tucson, Arizona
Study Facility
Tuscon, Arizona
Site Facility
Jonesboro, Arkansas
Site Facility
Little Rock, Arkansas
Research Facility
Anaheim, California
Research Site
Berkeley, California
Research Facility
Palm Desert, California
Research Facility
Pasadena, California
Research Facility
San Diego, California
Research Facility
San Ramon, California
Test Facility
Santa Rosa, California
Site Facility
Upland, California
Research Facility
Vista, California
Site Facility
Vista, California
Site Facility
Westlake Village, California
Test Facility
Denver, Colorado
Research Facility
Longmont, Colorado
Test Facility
New London, Connecticut
Study Facility
Waterbury, Connecticut
Research Facility
Washington D.C., District of Columbia
Research Facility
Boynton Beach, Florida
Site Facility
Clearwater, Florida
Site Facility
Daytona Beach, Florida
Research Facility
Gainesville, Florida
Research Site
Jacksonville, Florida
Site Facility
Jupiter, Florida
Test Facility
Miami, Florida
Research Facility
Pinellas Park, Florida
Research Facility
Plantation, Florida
Study Facility
South Miami, Florida
Showing 40 of 115 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.